Investing.com - Annexon (NASDAQ: ANNX) reported third quarter EPS of $-0.43, $0.08 better than the analyst estimate of $-0.51. Revenue for the quarter came in at $0.00 versus the...
Investing.com - Annexon (NASDAQ: ANNX) reported second quarter EPS of $-0.47, $0.07 better than the analyst estimate of $-0.54. Revenue for the quarter came in at $0.00 versus the...
By Davit KirakosyanHere is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades for Snowflake, MongoDB , Digital Turbine, and...
Investing.com - Annexon (NASDAQ: ANNX) reported first quarter EPS of $-52.00, $51.48 worse than the analyst estimate of $-0.52. Revenue for the quarter came in at $0.00 versus the...
Investing.com - Annexon (NASDAQ: ANNX) reported first quarter EPS of $-0.48, $0.05 better than the analyst estimate of $-0.53. Revenue for the quarter came in at $0.00 versus the...
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Technology, Consumer Goods and Consumer Services sectors led shares lower. At the close in...
Annexon, Inc. (Nasdaq: ANNX) today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic...
Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated...